HOBOKEN, NJ, April 05, 2012 (Press-News.org) Niiki Pharma Inc. announced the presentation of preclinical data for its novel anti-cancer compound, NKP-2235, at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago, Illinois. NKP-2235 is a first-in-class compound, and the first highly orally bioavailable gallium-based anti-cancer agent.
This breakthrough in cancer research is significant because, although other companies have tried developing gallium-based anti-cancer compounds before, they could not maintain therapeutic dosages safely and effectively in vivo.
"Developing a highly orally bioavailable gallium-based anti-cancer agent that stays intact and targets tumors has been a holy grail to those who have worked with gallium in the past," stated Dr. Hooshmand Sheshbaradaran, CEO of Niiki Pharma.
NKP-2235 is a novel agent that targets the endoplasmic reticulum. In laboratory studies, NKP-2235 has demonstrated single agent activity against multiple tumor types, including those resistant to chemotherapy. The data presented at AACR show that NKP-2235 also has synergistic activity when combined with other chemotherapy agents.
"The distinctive pattern of tumor cell death and the broad single agent activity of NKP-2235 make this a very interesting agent. The synergism data suggest that NKP-2235 will also work well in multi-agent chemotherapy regimens," said Dr. Angela Ogden, Chief Medical Officer at Niiki Pharma.
Niiki Pharma has obtained IND approval from the FDA and IRB approval to start the single agent Phase I trial on NKP-2235 at Indiana University's Melvin and Bren Simon Cancer Center in Indianapolis, Indiana. Companion diagnostics will be developed in parallel to enable NKP-2235 to be targeted to patients who can most benefit from treatment.
About NKP-2235
NKP-2235 is the second most advanced compound in Niiki Pharma's novel pipeline. NKP-2235 is a first-in-class orally available compound that targets the endoplasmic reticulum with a unique pattern of tumor cell killing. Independent of its anti-tumor activity, it can also prevent bone breakdown. NKP-2235 IND has been cleared and a Phase I trial will be initiated shortly. NKP-2235 was originally discovered by Professor Bernhard Keppler, University of Vienna, Austria.
About Niiki Pharma Inc.
Niiki Pharma (www.niikipharma.com) is a development focused oncology company specializing in first-in-class cancer treatments directed at novel tumor targets and related companion diagnostics.
Contacts
For Media Relations: Carolyn Rhinebarger, carolyn@luminovas.com, +1-919-604-4053.
For Investor Relations and Partnering: Ali Ardakani, ardakani@niikipharma.com, +1-201-238-2885
Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent
Niiki Pharma announced the presentation of preclinical data at the American Association for Cancer Research Annual Meeting in Chicago, Illinois for its novel compound, NKP-2235, the first highly orally bioavailable gallium-based anti-cancer agent.
2012-04-05
ELSE PRESS RELEASES FROM THIS DATE:
The Mash House Brewery Named A Designated Brewer On Hand For Brewgaloo Craft Beer Festival
2012-04-05
Dean Ogan, owner of Rocky Top Hospitality (http://www.rockytophospitality.com), has announced that its brewery, The Mash House, will be one of the designated brewers on hand at the Brewgaloo beer festival on Saturday, April 28 from 3 p.m. to 9 p.m. in downtown Raleigh's City Plaza. Bringing together local craft brewers, the Brewgaloo festival encourages consumers to eat, drink, purchase and think with a local mindset. Sponsored by Shop Local Raleigh, an organization in support of locally-owned independent businesses, Brewgaloo will include local breweries as well as local ...
Second Wind Takes Certified Account Executive College To Chicago, IL, April 17-18, 2012
2012-04-05
"As the economy moves into recovery, company marketing budgets will begin to open up. Advertising and marketing firms need to position their people and business strategies to take advantage of the resurgence in marketing activity," said Laurie Mikes, COO of Second Wind, a leading content, advice and service provider dedicated to the advertising and marketing industry. "Retaining accounts, picking up new accounts, successful strategic planning and writing winning new business proposals are critical to midsize and small advertising agencies, especially as the ...
Aitech's Flexible COTS Integrated Subsystem Functions Out of the Box
2012-04-05
Aitech Defense Systems Inc., a pioneer in true embedded and mission critical computing technologies for environmentally-demanding military, defense and aerospace applications, now offers the highly-integrated, compact RediBuilt rugged COTS computer that boots and executes your real-time operating system right out of the box. This flexible computer can accommodate either Intel or Freescale processors as well as a CompactPCI or OpenVPX backplane in a condensed package measuring less than 0.22 ft3, comparable in volume to a 1/4 ATR Short enclosure.
Designed to TRL 9 (Technical ...
Mims Distributing Selects MMI Public Relations As Agency Of Record
2012-04-05
Patty Briguglio, president of MMI Public Relations (http://www.mmipublicrelations.com), a Raleigh-based full-service public relations firm, has announced that the firm has been named the public relations agency of record for Mims Distributing Company (http://www.mimsdist.com), a beer distributor that services a nine-county area in and around the Triangle. MMI will assist Mims Distributing to generate heightened positive visibility for the company, its employees and its community outreach within the Triangle, and eventually the region and nation, through traditional and ...
You Can Protect Assets by Transferring Them to a Trust
2012-04-05
You Can Protect Assets by Transferring Them to a Trust
Among the various estate-planning tools, trusts are perhaps the most effective in protecting assets. Wills provide a method of distributing your assets when you die, while trusts are legal entities that hold them and keep them safe. Credit shelter trusts, generation-skipping trusts and discretionary spendthrift trusts are especially useful because they generally cannot be accessed by creditors or former spouses.
Claims by Creditors, Ex-Spouses
If you have an ownership interest in a business, for example, it ...
Loftware Print Server v10.0 Acheives GS1 US Certification
2012-04-05
Loftware, the global leader in Enterprise Lifecycle Printing (ELP) software has successfully achieved the highly acclaimed GS1 Certification for the Loftware Print Server v10.0. As a long-time GS1 US Solution Partner, Loftware has worked alongside GS1 for over 10 years supporting the international GS1 standards and guidelines for barcode label printing. Attaining GS1 US Certification of Loftware Print Server 10.0 underscores the ongoing commitment to offer customers support for the latest compliance standards they have grown to expect from Loftware.
GS1, an international ...
Stickleback genome holds clues to adaptive evolution
2012-04-05
Scientists searching for genetic clues to vertebrate evolution have long been fascinated by the tiny marine stickleback fish, known for its ability to adapt and thrive in salty oceans or freshwater streams around the world. Now, a team of researchers from the Broad Institute and Stanford University has analyzed the entire genetic sequence of 21 threespine sticklebacks and identified which regions of the genome regulate their ability to adapt to such markedly different environments. The findings appear in the April 5 issue of Nature.
"Sticklebacks are essentially the 'Darwin's ...
Scientists uncover multiple faces of deadly breast cancer
2012-04-05
An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated.
The journal Nature has just published the team's findings online in the paper The clonal and mutational evolution spectrum of primary triple negative breast cancers.
The study is the largest genetic analysis of what were thought to be triple negative breast cancer tumours.
The 59 scientists involved in this study expected to see similar gene profiles when they mapped on computer the genomes ...
Arsenic turns stem cells cancerous, spurring tumor growth
2012-04-05
Researchers at the National Institutes of Health have discovered how exposure to arsenic can turn normal stem cells into cancer stem cells and spur tumor growth. Inorganic arsenic, which affects the drinking water of millions of people worldwide, has been previously shown to be a human carcinogen. A growing body of evidence suggests that cancer is a stem-cell based disease. Normal stem cells are essential to normal tissue regeneration, and to the stability of organisms and processes. But cancer stem cells are thought to be the driving force for the formation, growth, and ...
New forage plant prepares farmers for climate changes
2012-04-05
Sorghum, or durra, is an important forage crop in many countries, for example the USA, Africa, China and Australia.
The plant is grown instead of corn because it produces more biomass and better withstands long periods of drought.
However, when exposed to drought, the sorghum plant produces large amounts of dhurrin, which forms toxic cyanide, i.e. Prussic acid.
Forced to discard crops
Farmers thus face a big dilemma. During a period of drought when they most need food for their animals, they are often forced to discard their sorghum because they do not know how ...
LAST 30 PRESS RELEASES:
Study finds link between colorblindness and death from bladder cancer
Tailored treatment approach shows promise for reducing suicide and self-harm risk in teens and young adults
Call for papers: AI in biochar research for sustainable land ecosystems
Methane eating microbes turn a powerful greenhouse gas into green plastics, feed, and fuel
Hidden nitrogen in China’s rice paddies could cut fertilizer use
Texas A&M researchers expose hidden risks of firefighter gear in an effort to improve safety and performance
Wood burning in homes drives dangerous air pollution in winter
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 23, 2026
ISSCR statement in response to new NIH policy on research using human fetal tissue (Notice NOT-OD-26-028)
Biologists and engineers follow goopy clues to plant-wilting bacteria
What do rats remember? IU research pushes the boundaries on what animal models can tell us about human memory
Frontiers Science House: did you miss it? Fresh stories from Davos – end of week wrap
Watching forests grow from space
New grounded theory reveals why hybrid delivery systems work the way they do
CDI scientist joins NIH group to improve post-stem cell transplant patient evaluation
Uncovering cancer's hidden oncRNA signatures: From discovery to liquid biopsy
Multiple maternal chronic conditions and risk of severe neonatal morbidity and mortality
Interactive virtual assistant for health promotion among older adults with type 2 diabetes
Ion accumulation in liquid–liquid phase separation regulates biomolecule localization
Hemispheric asymmetry in the genetic overlap between schizophrenia and white matter microstructure
Research Article | Evaluation of ten satellite-based and reanalysis precipitation datasets on a daily basis for Czechia (2001–2021)
Nano-immunotherapy synergizing ferroptosis and STING activation in metastatic bladder cancer
Insilico Medicine receives IND approval from FDA for ISM8969, an AI-empowered potential best-in-class NLRP3 inhibitor
Combined aerobic-resistance exercise: Dual efficacy and efficiency for hepatic steatosis
Expert consensus outlines a standardized framework to evaluate clinical large language models
Bioengineered tissue as a revolutionary treatment for secondary lymphedema
Forty years of tracking trees reveals how global change is impacting Amazon and Andean Forest diversity
Breathing disruptions during sleep widespread in newborns with severe spina bifida
Whales may divide resources to co-exist under pressures from climate change
Why wetland restoration needs citizens on the ground
[Press-News.org] Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer AgentNiiki Pharma announced the presentation of preclinical data at the American Association for Cancer Research Annual Meeting in Chicago, Illinois for its novel compound, NKP-2235, the first highly orally bioavailable gallium-based anti-cancer agent.